Wall Street Business News

Andiamo Corporation Makes Decision on New Hydrogen Product

February 14, 2017
  0
  • Facebook
  • Twitter
  • Google+
  • Facebook
  • Twitter
  • Google+
Latest News
  • ROSEN, A HIGHLY RANKED LAW FIRM, Reminds RCI Hospitality Holdings, Inc. Investors of Lead Plaintiff Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RICK
  • Sprint Shareholder Litigation: Block & Leviton LLP Encourages Shareholders To Contact The Firm
  • REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
  • ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
  • Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
  • Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
  • Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
  • Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
Copyright 2018 Wall Street Business News
  • Pink Sheets
  • OTCBB

Wall Street Business News

Latest News
  • ROSEN, A HIGHLY RANKED LAW FIRM, Reminds RCI Hospitality Holdings, Inc. Investors of Lead Plaintiff Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RICK
  • Sprint Shareholder Litigation: Block & Leviton LLP Encourages Shareholders To Contact The Firm
  • REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
  • ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
  • Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association

Start typing and press Enter to search